More blood pressure, heart failure medications added to FDA recall

A probable carcinogen called N- nitrosodimethylamine (NDMA) was found in the drugs.

More companies have been added to an FDA recall of blood pressure medicine containing a possible carcinogen.

Click or tap here to see the updated list, which expands upon the original valsartan-containing drugs to at least 40 products with varying pill counts.

An impurity called N-nitrosodimethylamine (NDMA) was found in the drugs. NDMA is classified as a probable human carcinogen based on lab tests. The FDA says the list now includes valsartan-containing products manufactured by Hetero Labs Limited, in India, labeled as Camber Pharmaceuticals Inc.

 

 

The US Food and Drug Administration expanded the list of drugs being recalled that contain valsartan. The drug is used as a component in a set of drugs used to treat heart failure and blood pressure.

New to the list are some valsartan products manufactured by Hetero Labs Ltd. in India, which are labeled as Camber Pharmaceuticals Inc. Test results show that some of the products may be tainted.
The FDA announced a valsartan recall in July after lab tests revealed that some drugs could have been tainted with a substance linked to higher risk of cancer. The drug had been recalled in 22 other countries. The expanded recall includes some drugs that contain valsartan and hydrochlorothisazide. Not all of the drugs containing valsartan were affected.

FDA expands recall of blood pressure drug valsartan due to cancer concern

 
More drugs containing valsartan have been recalled
Not all valsartan products are being recalled
Talk to your doctor before you stop taking these medications
(CNN)The US Food and Drug Administration expanded the list of drugs being recalled that contain valsartan. The drug is used as a component in a set of drugs used to treat heart failure and blood pressure.

New to the list are some valsartan products manufactured by Hetero Labs Ltd. in India, which are labeled as Camber Pharmaceuticals Inc. Test results show that some of the products may be tainted.
The FDA announced a valsartan recall in July after lab tests revealed that some drugs could have been tainted with a substance linked to higher risk of cancer. The drug had been recalled in 22 other countries. The expanded recall includes some drugs that contain valsartan and hydrochlorothisazide. Not all of the drugs containing valsartan were affected.

Content by ProColombia
Embark on a taste voyage through this country
Set off on a culinary adventure around Colombia.
N-nitrosodimethylamine or NDMA, the impurity the lab tests found, is considered a possible carcinogen by the US Environmental Protection Agency. It is an organic chemical that has been used to make liquid rocket fuel, and it can be unintentionally introduced through certain chemical reactions. It’s a byproduct of the manufacturing of some pesticides and fish processing.

The medicines that are now a part of this expanded list in the recall are tablets sold by AvKare, A-S Medication Solutions LLC, Bryant Ranch Prepack Inc, Camber Pharmaceuticals, Inc. H J Harkins Company, Northwind Pharmaceuticals, NuCare Pharmaceuticals Inc., Prinston Pharmaceutical Inc. (labeled as Solco Healthcare LLC), Proficient Rx LP, Remedy Repack, Teva Pharmaceuticals (labeled as Major Pharmaceuticals), Teva Pharmaceuticals USA (labeled as Actavis).

The FDA also published a list of valsartan products that are not currently recalled. Only the drugs suspected of being tainted with NDMA are on the recall list. If you are taking a valsartan drug, look for the company name on your prescription bottle. If the information isn’t on the label, you can call your pharmacy for those details.
The recalled medicine is linked to a manufacturer in China. The substances were supplied by Zhejiang Huahai Pharmaceuticals, based in Linhai, in eastern China, which said it notified authorities as soon as it identified the impurity.

“We published our recall notice at midday on July 13 in China and overseas, and published the US market recall notice on July 14 Beijing time … all the drug materials for the Chinese market were recalled by July 23,” the company said in a statement to the Shanghai stock exchange last month.
The FDA said on its website that it’s working with drug manufacturers “to ensure future valsartan active pharmaceutical ingredients are not at risk.”

Categories
NewsNews
No Comment

Leave a Reply

*

*

RELATED BY